Trade patterns of Chinese pharmaceutical raw materials need to be improved
As the world's largest raw material drug production and exporting country, China' can produce more than 1,500 species of chemical raw materials. Since 2001, annual exports of bulk drugs increase by more than 24%.
Although the API manufacturers’ productions are influenced by the human cost, materials prices, exchange rate fluctuations and other factors, the export value still increase.
Annual global API market is about $ 80 billion. The procurement market $ 30 billion. Chinese pharmaceutical raw materials suppliers accounted for almost half of the world's pharmaceutical raw materials procurement market share. In addition, some bulk products in a dominant position in the global market, such as VC, paracetamol, penicillin industrial salt, sodium saccharin, etc., this pattern in the short term there will be no major change in international prices rise with China's prices. China chemical raw materials export volume in 2012 may be reduced or lower rate of increase, but because of the price increase, total exports will keep growing, is expected to exceed 20%.
Price changes in regulation of the relationship between supply and demand, production capacity has not been released, and supply tight, prices, and expected the coming period will run high steady. On the basis of maintaining the advantage of traditional bulk chemical raw materials, Chinese manufacturers are actively seeking a new driving force for sustainable development. Insiders pointed out that the rapid development of the global generics market more than the number of patent medicine expires, the Chinese pharmaceutical raw materials manufacturers in the development of generic formulations and R & D patent expiration drug bulk drugs in two ways to seek new growth points.
Chinese pharmaceutical companies also process innovative varieties, the characteristics of bulk drugs and pharmaceutical raw materials R & D tracking patent expiration drug seeking breakthroughs, the formation of the layout of the dislocation, enhance their international competitiveness. Has been in Asia, Europe and North America is the traditional export markets for China's API, the three markets accounted for the proportion of Chinese exports of bulk drugs market as high as 88.9%, the Asian market is 41.3 percent champion.
From January to March, price of China's API exports to the three major markets increases. The exports increase in more than 40%. For chia seeds purchase to the United States, India, Germany, Japan and the Netherlands, China's exports ranging are from 5.44% to 13.95%. In export volume, with the exception of India, the first three months of this year, Chinese exports to the four other countries have different degrees of decline.
On the other hand, exports for Iraq, Tajikistan, and Latvia increase considerably. It reflects the positive achievements of the Chinese pharmaceutical raw materials’ export market. Among the three trading modes, average price of general trade is equivalent to the price of processing trade. Price of the later is 5 times than the average price of general trade. For exports alone, the proportion of general trade is as high as 86.7%. During the time of January to March, the average export price increase greatly. The second one is the processing trade. The processing trade increased by only 6%.Source:http://www.cospcn.com
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
pharmaceutical'>http://www.cospcn.com">pharmaceutical raw materials